World Journal of Gastroenterology

Article	Citations
Pancreatic cancer: A review of epidemiology, trend, and risk factors	253
Gut microbiota in obesity	235
Epidemiology of stomach cancer	165
Gut microbiota, inflammatory bowel disease and colorectal cancer	140
Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment	107
Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma	93
Updates on global epidemiology, risk and prognostic factors of gastric cancer	77
Pancreatic cancer in 2021: What you need to know to win	77
Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis	74
Current guidelines for the management of celiac disease: A systematic review with comparative analysis	74
Artificial intelligence applications in inflammatory bowel disease: Emerging technologies and future directions	70
Management of cholelithiasis with choledocholithiasis: Endoscopic and surgical approaches	69
Effect of probiotic Lactobacillus plantarum Dad-13 powder consumption on the gut microbiota and intestinal health of overweight adults	68
Artificial intelligence in gastroenterology: A state-of-the-art review	65
Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives	61
From hepatitis A to E: A critical review of viral hepatitis	60
Immune checkpoint inhibitor-related hepatotoxicity: A review	60
High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: A systematic review and meta-analysis of autopsy data	59
Chinese guidelines on the management of liver cirrhosis (abbreviated version)	56
Helicobacter pylori: Commensal, symbiont or pathogen?	55
Early-onset colorectal cancer: A review of current knowledge	54
Machine learning models and over-fitting considerations	54
Artificial intelligence in the diagnosis and management of colorectal cancer liver metastases	53
Fecal microbiota transplantation ameliorates experimental colitis via gut microbiota and T-cell modulation	51
Gut microbiota in various childhood disorders: Implication and indications	50

Molecular overview of progressive familial intrahepatic cholestasis	49
Predictors of early and late hepatocellular carcinoma recurrence	49
Gut bless you: The microbiota-gut-brain axis in irritable bowel syndrome	49
Shared decision-making in the management of patients with inflammatory bowel disease	49
BRCA mutated pancreatic cancer: A change is coming	49
Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions	49
Liver injury in the era of COVID-19	49
Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?	48
Antimicrobial peptides and the gut microbiome in inflammatory bowel disease	48
Oral microbiome and pancreatic cancer	47
Altered metabolism of bile acids correlates with clinical parameters and the gut microbiota in patients with diarrhea-predominant irritable bowel syndrome	47
International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: A joinpoint regression analysis	46
Viral hepatitis update: Progress and perspectives	45
Sarcopenia in hepatocellular carcinoma: Current knowledge and future directions	45
Lactobacillus bulgaricus inhibits colitis-associated cancer via a negative regulation of intestinal inflammation in azoxymethane/dextran sodium sulfate model	45
Effect of berberine on hyperglycaemia and gut microbiota composition in type 2 diabetic Goto-Kakizaki rats	45
Prognostic role of artificial intelligence among patients with hepatocellular cancer: A systematic review	45
Microbiota revolution: How gut microbes regulate our lives	44
Prevention of vertical transmission of hepatitis B virus infection	44
Artificial intelligence based real-time microcirculation analysis system for laparoscopic colorectal surgery	42
Impaired coagulation, liver dysfunction and COVID-19: Discovering an intriguing relationship	42
Diabetes and pancreatic cancer: Exploring the two-way traffic	42
Immunotherapy for hepatocellular carcinoma: Current status and future perspectives	41
Pathophysiological mechanisms underlying gastrointestinal symptoms in patients with COVID-19	41
Endoscopic diagnosis and treatment of gastric dysplasia and early cancer: Current evidence and what the future may hold	41
T cells in pancreatic cancer stroma	41
COVID-19-associated diarrhea	40
Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link	40
Relationship between clinical features and intestinal microbiota in Chinese patients with ulcerative colitis	40
Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients	40
Viral hepatitis: Past, present, and future	40
Radiomics and machine learning applications in rectal cancer: Current update and future perspectives	40
Artificial intelligence-assisted colonoscopy: A review of current state of practice and research	38
Mucosal lesions of the upper gastrointestinal tract in patients with ulcerative colitis: A review	37
COVID-19 and the gastrointestinal tract: source of infection or merely a target of the inflammatory process following SARS-CoV-2 infection?	36
Lipotoxic hepatocyte-derived exosomal miR-1297 promotes hepatic stellate cell activation through the PTEN signaling pathway in metabolic-associated fatty liver disease	36
Update on the management of sigmoid diverticulitis	36
COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms	36
Intraoperative use of indocyanine green fluorescence imaging in rectal cancer surgery: The state of the art	36
Rectal neuroendocrine tumors: Current advances in management, treatment, and surveillance	35
Alteration of fecal tryptophan metabolism correlates with shifted microbiota and may be involved in pathogenesis of colorectal cancer	34
Antibiotics, gut microbiota, and irritable bowel syndrome: What are the relations?	34
Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease	34
Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies	34
Microbiota shaping — the effects of probiotics, prebiotics, and fecal microbiota transplant on cognitive functions: A systematic review	33
Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons	33
Quercetin exerts anti-inflammatory effectsviainhibiting tumor necrosis factor-α-induced matrix metalloproteinase-9 expression in normal human gastric epithelial cells	33
Update on the management and treatment of viral hepatitis	33
Endoscopic submucosal dissection vs endoscopic mucosal resection for colorectal polyps: A meta-analysis and meta-regression with single arm analysis	33
Gegen Qinlian decoction enhances immunity and protects intestinal barrier function in colorectal cancer patients via gut microbiota	33

Novel drug delivery systems for inflammatory bowel disease	32
Role of bile acids in liver diseases mediated by the gut microbiome	31
Nuclear factor erythroid 2-related factor 2-mediated signaling and metabolic associated fatty liver disease	31
Can control of gut microbiota be a future therapeutic option for inflammatory bowel disease?	31
Acute kidney injury and hepatorenal syndrome in cirrhosis	31
Metabolic complications of hepatitis C virus infection	31
Celiac disease: From genetics to epigenetics	31
Hepatitis B virus infection and hepatocellular carcinoma in sub-Saharan Africa: Implications for elimination of viral hepatitis by 2030?	31
Invasive fungal infection before and after liver transplantation	31
Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort	30
Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure	30
Gut microbiome in acute pancreatitis: A review based on current literature	30
Local ablation of pancreatic tumors: State of the art and future perspectives	30
Exosomal microRNA-588 from M2 polarized macrophages contributes to cisplatin resistance of gastric cancer cells	30
Intestinal ultrasound as a non-invasive tool to monitor inflammatory bowel disease activity and guide clinical decision making	30
Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management	30
Efficacy and safety of anti-hepatic fibrosis drugs	29
Circular RNA circVAPA promotes chemotherapy drug resistance in gastric cancer progression by regulating miR-125b-5p/STAT3 axis	29
Effects of sepsis and its treatment measures on intestinal flora structure in critical care patients	29
Role of baicalin as a potential therapeutic agent in hepatobiliary and gastrointestinal disorders: A review	29
Impact of Helicobacter pylori infection on gut microbiota	28
Current trends in acute pancreatitis: Diagnostic and therapeutic challenges	28
Determination of gluten immunogenic peptides for the management of the treatment adherence of celiac disease: A systematic review	28
Gut microbiota dysbiosis in Chinese children with type 1 diabetes mellitus: An observational study	28
How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician	28
Repurposing metformin for the treatment of gastrointestinal cancer	28
Advances in traction methods for endoscopic submucosal dissection: What is the best traction method and traction direction?	28
Fusobacterium nucleatum colonization is associated with decreased survival of helicobacter pylori-positive gastric cancer patients	27
Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end	27
Gut mucosal microbiota profiles linked to colorectal cancer recurrence	27
Neurological and psychiatric effects of hepatitis C virus infection	27
Gastrointestinal mucosal immunity and COVID-19	27
Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities	27
Changes in gut microbiota composition and diversity associated with post-cholecystectomy diarrhea	26
Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease	26
Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma	26
Non-occlusive mesenteric ischemia: Diagnostic challenges and perspectives in the era of artificial intelligence	26
Interaction between hepatitis B virus and SARS-CoV-2 infections	26
Human hepatitis viruses-associated cutaneous and systemic vasculitis	26
Potential risk factors for constipation in the community	26
Endoscopic management of difficult common bile duct stones: Where are we now? A comprehensive review	26
Viral hepatitis: Milestones, unresolved issues, and future goals	26
Risk of hepatocellular carcinoma after hepatitis C virus cure	26
G protein-coupled receptors as potential targets for nonalcoholic fatty liver disease treatment	26
Paediatric gastrointestinal disorders in SARS-CoV-2 infection: Epidemiological and clinical implications	25
Textbook outcomes in hepatobiliary and pancreatic surgery	25
Challenges and opportunities in the application of artificial intelligence in gastroenterology and hepatology	25
Epidemiology of small intestinal bacterial overgrowth	25
Autoimmune liver diseases in systemic rheumatic diseases	25
Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect	25
Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome	25
Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment	25
Abnormal liver chemistries as a predictor of COVID-19 severity and clinical outcomes in hospitalized patients	24
Chronic rejection after liver transplantation: Opening the Pandora’s box	24
Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis	24
Role of modern radiotherapy in managing patients with hepatocellular carcinoma	24
Comparative study on artificial intelligence systems for detecting early esophageal squamous cell carcinoma between narrow-band and white-light imaging	24
Gastrointestinal involvement in paediatric COVID-19 — from pathogenesis to clinical management: A comprehensive review	24
Abdominal and gastrointestinal manifestations in COVID-19 patients: Is imaging useful?	24
Ischemic bowel disease in 2021	24
Liver dysfunction and SARS-CoV-2 infection	23
Global research trends in the microbiome related to irritable bowel syndrome: A bibliometric and visualized study	23
Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: A cross-sectional and longitudinal analysis	23
Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion	23
Risk factors for lymph node metastasis in T1 esophageal squamous cell carcinoma: A systematic review and meta-analysis	23
Pancreatic adenocarcinoma: A review of recent paradigms and advances in epidemiology, clinical diagnosis and management	23
Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma	23
Artificial intelligence for the early detection of colorectal cancer: A comprehensive review of its advantages and misconceptions	23
Artificial intelligence and inflammatory bowel disease: Where are we going?	23
Experimental models of metabolic and alcoholic fatty liver disease	23
Intermittent hypoxia is involved in gut microbial dysbiosis in type 2 diabetes mellitus and obstructive sleep apnea-hypopnea syndrome	23
Microbiome changes in the gastric mucosa and gastric juice in different histological stages of Helicobacter pylori-negative gastric cancers	23
Hybrid XGBoost model with hyperparameter tuning for prediction of liver disease with better accuracy	22
Microbiota of the gastrointestinal tract: Friend or foe?	22
Pancreatic acinar cell carcinoma: A comprehensive review	22
Liver injury in COVID-19: Detection, pathogenesis, and treatment	22
An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms	22
Gut microbiota mediated molecular events and therapy in liver diseases	22
Radiomics for predicting perineural invasion status in rectal cancer	21
Stem cell injection for complex anal fistula in Crohn’s disease: A single-center experience	21

Evolving role of artificial intelligence in gastrointestinal endoscopy	21
Fecal microbiota transplantation in the metabolic diseases: Current status and perspectives	21
Sex-based differences in histology, staging, and prognosis among 2983 gastric cancer surgery patients	21
Ubiquitin-specific protease 15 contributes to gastric cancer progression by regulating the Wnt/β-catenin signaling pathway	21
Probiotics and postbiotics in colorectal cancer: Prevention and complementary therapy	21
Systemic treatment for metastatic colorectal cancer	21
Emerging use of artificial intelligence in inflammatory bowel disease	21
Fusobacterium nucleatum promotes colon cancer progression by changing the mucosal microbiota and colon transcriptome in a mouse model	21
Hepatitis B core antigen modulates exosomal miR-135a to target vesicle-associated membrane protein 2 promoting chemoresistance in hepatocellular carcinoma	21
Adult pancreatoblastoma: Current concepts in pathology	21
Management of metabolic-associated fatty liver disease: The diabetology perspective	21
Study of tumor necrosis factor receptor in the inflammatory bowel disease	21
Gossip in the gut: Quorum sensing, a new player in the host-microbiota interactions	21
Coronavirus disease–2019 and the intestinal tract: An overview	21
Clinical characteristics and outcomes of patients with hepatic angiomyolipoma: A literature review	21
Nanotheranostics: A powerful next-generation solution to tackle hepatocellular carcinoma	21
Neutrophil extracellular traps participate in the development of cancer-associated thrombosis in patients with gastric cancer	21
B cells in pancreatic cancer stroma	21
Innate and adaptive immune escape mechanisms of hepatitis B virus	21
Early gastric cancer: A challenge in Western countries	20
Endoscopic ultrasound fine needle aspiration vs fine needle biopsy for pancreatic masses, subepithelial lesions, and lymph nodes	20
Peritoneal dissemination of pancreatic cancer caused by endoscopic ultrasound-guided fine needle aspiration: A case report and literature review	20
Response of gut microbiota to serum metabolome changes in intrahepatic cholestasis of pregnant patients	20
Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects	20
Effect of liver inflammation on accuracy of FibroScan device in assessing liver fibrosis stage in patients with chronic hepatitis B virus infection	20
Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy	20
Requirements for implementation of artificial intelligence in the practice of gastrointestinal pathology	20
Anabolic androgenic steroid-induced liver injury: An update	20
Diagnosis and treatment of iron-deficiency anemia in gastrointestinal bleeding: A systematic review	20
Chronic intestinal failure and short bowel syndrome in Crohn’s disease	20
Role of microbial dysbiosis in the pathogenesis of esophageal mucosal disease: A paradigm shift from acid to bacteria?	20
Pancreatitis and pancreatic cancer: A case of the chicken or the egg	20
Hepatitis E in solid organ transplant recipients: A systematic review and meta-analysis	20
Emerging role of the gut microbiome in post-infectious irritable bowel syndrome: A literature review	20
Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges	20
Zinc oxide nanoparticles reduce the chemoresistance of gastric cancer by inhibiting autophagy	19
Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures	19
Altered gut microbiota patterns in COVID-19: Markers for inflammation and disease severity	19
Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease	19
Gastric acid level of humans must decrease in the future	19
Radiomics for the detection of microvascular invasion in hepatocellular carcinoma	19
Endothelial cells and blood vessels are major targets for COVID-19-induced tissue injury and spreading to various organs	19
Prediction of microvascular invasion in solitary hepatocellular carcinoma ≤ 5 cm based on computed tomography radiomics	19
Autoimmune pancreatitis and pancreatic cancer: Epidemiological aspects and immunological considerations	19
Recurrence rates after endoscopic resection of large colorectal polyps: A systematic review and meta-analysis	19
Viscoelastic tests in liver disease: where do we stand now?	19
Obesity and novel management of inflammatory bowel disease	19
Incidence and clinical characteristics of hypertriglyceridemic acute pancreatitis: A retrospective single-center study	19
Surrogate markers of mucosal healing in inflammatory bowel disease: A systematic review	19
Sinapic acid ameliorates D-galactosamine/lipopolysaccharide-induced fulminant hepatitis in rats: Role of nuclear factor erythroid-related factor 2/heme oxygenase-1 pathways	18
Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment	18
Nanotechnology for colorectal cancer detection and treatment	18
Recent advances in artificial intelligence for pancreatic ductal adenocarcinoma	18
Current understanding of the impact of COVID-19 on gastrointestinal disease: Challenges and openings	18
Partially hydrolyzed guar gum attenuates non-alcoholic fatty liver disease in mice through the gut-liver axis	18
Impact of cytokine storm and systemic inflammation on liver impairment patients infected by SARS-CoV-2: Prospective therapeutic challenges	18
COVID-19 and its effects on the digestive system	18
Screening for nonalcoholic fatty liver disease-when, who and how?	18
Gut dysbiosis and small intestinal bacterial overgrowth as independent forms of gut microbiota disorders in cirrhosis	18
Artificial intelligence for early detection of pancreatic adenocarcinoma: The future is promising	18
Celiac Disease in Asia beyond the Middle East and Indian subcontinent: Epidemiological burden and diagnostic barriers	18
Drug-induced autoimmune hepatitis: A minireview	18
Crohn’s disease in low and lower-middle income countries: A scoping review	18
Epidemiologic and socioeconomic factors impacting hepatitis B virus and related hepatocellular carcinoma	18
Liver disease and COVID-19: The link with oxidative stress, antioxidants and nutrition	18
Survival and outcomes for co-infection of chronic hepatitis C with and without cirrhosis and COVID-19: A multicenter retrospective study	18
Associations between serum uric acid and hepatobiliary-pancreatic cancer: A cohort study	18
Fecal microbiota transplantation for irritable bowel syndrome: An intervention for the 21st century	18
Fluorescent cholangiography: An up-to-date overview twelve years after the first clinical application	18
Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study	18
Gastric pentadecapeptide BPC 157 in cytoprotection to resolve major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome	17
Updates in diagnosis and management of pancreatic cysts	17
Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond	17
Neurological manifestations of hepatitis E virus infection: An overview	17
Insight into molecular mechanisms underlying hepatic dysfunction in severe COVID-19 patients using systems biology	17
Antifungal activity and antidiarrheal activity via antimotility mechanisms of (-)-fenchone in experimental models	17
Genetic variant of cyclooxygenase-2 in gastric cancer: More inflammation and susceptibility	17
Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements	17
Fatty liver is an independent risk factor for gallbladder polyps	17
Hepatitis C virus micro-elimination: Where do we stand?	17
Focus on gastroesophageal reflux disease in patients with cystic fibrosis	17
Mapping the global research landscape on nutrition and the gut microbiota: Visualization and bibliometric analysis	17
Dihydromyricetin ameliorates chronic liver injury by reducing pyroptosis	17
COVID-19 and comorbidities of hepatic diseases in a global perspective	17
Gastrointestinal and hepatic diseases during the COVID-19 pandemic: Manifestations, mechanism and management	17
Application of artificial intelligence in preoperative imaging of hepatocellular carcinoma: Current status and future perspectives	17
Attention deficit hyperactivity disorder and gastrointestinal morbidity in a large cohort of young adults	17
Prognostic factors of minimally invasive surgery for gastric cancer: Does robotic gastrectomy bring oncological benefit?	17
Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome	17
Helicobacter pylori infection: How does age influence the inflammatory pattern?	17
Huanglian decoction suppresses the growth of hepatocellular carcinoma cells by reducing CCNB1 expression	17
Neuropilin-1: A feasible link between liver pathologies and COVID-19	17
Endoscopic anti-reflux therapy for gastroesophageal reflux disease	17
Hericium erinaceus, a medicinal fungus with a centuries-old history: Evidence in gastrointestinal diseases	17
Recent advances in the diagnostic evaluation of pancreatic cystic lesions	17